Suppliers and packagers for generic pharmaceutical drug: pitavastatin calcium

pitavastatin calcium

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363	NDA	Kowa Pharmaceuticals America, Inc.	66869-104-90	90 TABLET, FILM COATED in 1 BOTTLE, DISPENSING (66869-104-90)	2019-05-16
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363	NDA	Kowa Pharmaceuticals America, Inc.	66869-204-90	90 TABLET, FILM COATED in 1 BOTTLE, DISPENSING (66869-204-90)	2019-05-16
Kowa Co	LIVALO	pitavastatin calcium	TABLET;ORAL	022363	NDA	Kowa Pharmaceuticals America, Inc.	66869-404-90	90 TABLET, FILM COATED in 1 BOTTLE, DISPENSING (66869-404-90)	2019-05-16

Pitavastatin Calcium: Supplier Landscape Analysis

Last updated: February 19, 2026

This report identifies key suppliers for pitavastatin calcium, a statin medication, detailing their manufacturing capabilities, regulatory compliance, and market presence. Understanding this supplier base is critical for pharmaceutical companies managing supply chain resilience and cost optimization for pitavastatin calcium production.

Who are the Primary Manufacturers of Pitavastatin Calcium API?

The global supply of pitavastatin calcium active pharmaceutical ingredient (API) is concentrated among a select group of manufacturers, primarily located in Asia. These companies possess the necessary chemical synthesis expertise and large-scale production capacity to meet market demand.

Key manufacturers include:

• Kowa Pharmaceutical Co., Ltd.: As the originator of pitavastatin, Kowa has significant manufacturing capabilities and intellectual property.
• Cheman N.V.: A European manufacturer with a strong reputation for API production.
• Zhejiang Huahai Pharmaceutical Co., Ltd.: A major Chinese API producer with a broad portfolio of cardiovascular drugs.
• Lupin Ltd.: An Indian pharmaceutical company with established API manufacturing facilities.
• Dr. Reddy's Laboratories Ltd.: Another prominent Indian API supplier with extensive global reach.
• Cipla Ltd.: An Indian multinational pharmaceutical company with robust API manufacturing operations.
• Sun Pharmaceutical Industries Ltd.: A leading Indian pharmaceutical company that manufactures APIs for various therapeutic areas.
• Aarti Drugs Ltd.: An Indian manufacturer specializing in APIs and intermediates.
• Cadila Healthcare Ltd. (now Zydus Lifesciences): An Indian pharmaceutical company with significant API production capacity.
• Yingde Hongrun Pharmaceutical Co., Ltd.: A Chinese manufacturer contributing to the pitavastatin calcium supply.
• Anqiu Lu'an Pharmaceutical Co., Ltd.: Another Chinese entity involved in the production of pitavastatin calcium.

These suppliers operate at various scales, from specialized contract manufacturers to large integrated pharmaceutical companies that produce APIs for both captive use and the merchant market. Their geographical distribution is predominantly in China and India, leveraging cost advantages and established chemical manufacturing infrastructure.

What are the Regulatory Approvals Held by Pitavastatin Calcium Suppliers?

Regulatory approvals are a critical determinant of supplier reliability and market access. Manufacturers must adhere to stringent Good Manufacturing Practices (GMP) mandated by major regulatory bodies.

Key regulatory compliance standards and agencies include:

• U.S. Food and Drug Administration (FDA): Site inspections and drug master file (DMF) submissions are required for U.S. market access.
• European Medicines Agency (EMA): Compliance with EU GMP guidelines and Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) are essential.
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan: Japanese regulatory requirements are rigorous, especially for imported APIs.
• Central Drugs Standard Control Organisation (CDSCO), India: Indian regulatory oversight for domestic and export markets.
• China National Medical Products Administration (NMPA): The primary regulator for the Chinese pharmaceutical market.

Manufacturers often hold multiple accreditations, demonstrating their ability to supply to diverse international markets. The presence of a U.S. DMF or an EU CEP is a strong indicator of a supplier's readiness for regulated markets. For instance, Zhejiang Huahai Pharmaceutical has a history of FDA and EMA approvals for its APIs. Similarly, Lupin Ltd. and Dr. Reddy's Laboratories have consistently received approvals from these agencies for their manufacturing sites and products.

The process of obtaining and maintaining these approvals involves regular audits and adherence to evolving regulatory standards. Suppliers that consistently pass these audits and maintain a strong regulatory track record are preferred for long-term supply agreements.

What is the Production Capacity and Technological Capability of Key Suppliers?

The production capacity and technological sophistication of pitavastatin calcium suppliers vary, impacting their ability to handle large-volume orders and ensure consistent quality.

• Scale of Production: Leading suppliers such as Zhejiang Huahai Pharmaceutical and major Indian players like Lupin and Dr. Reddy's possess multi-ton API manufacturing capacities. This scale is necessary to meet the global demand for generic pitavastatin calcium, which has grown significantly since patent expirations.
• Synthesis Route Expertise: The synthesis of pitavastatin calcium involves multiple chemical steps, requiring expertise in chiral synthesis and purification. Manufacturers with optimized and robust synthesis routes can achieve higher yields and purity, leading to cost efficiencies and superior product quality. Kowa Pharmaceutical, as the innovator, has likely developed highly efficient proprietary routes. Generic manufacturers often develop alternative, non-infringing synthesis pathways.
• Quality Control and Assurance: Advanced analytical laboratories equipped with high-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) are standard. These technologies are essential for impurity profiling, polymorph identification, and ensuring batch-to-batch consistency.
• Environmental, Health, and Safety (EHS) Standards: Modern API manufacturers invest in sophisticated waste treatment and emission control systems to comply with increasingly stringent environmental regulations. This is particularly relevant for chemical synthesis processes.

The technological capability also extends to process development and optimization, enabling suppliers to reduce manufacturing costs, improve sustainability, and adapt to market demand fluctuations. Companies that have invested in process chemistry research and development are better positioned to offer competitive pricing and reliable supply.

How Does the Patent Landscape Affect the Pitavastatin Calcium Supplier Market?

The patent landscape for pitavastatin calcium has significantly shaped the current supplier market, transitioning from a period of originator exclusivity to a more competitive generic environment.

• Original Patents: Pitavastatin was originally developed by Kowa Pharmaceutical. Key patents covered the compound itself, its synthesis, and specific formulations. These patents provided market exclusivity for a defined period.
• Generic Entry: Upon the expiry of primary compound patents in major markets (e.g., U.S., Europe), generic manufacturers began entering the market. This typically occurred from the mid-2010s onwards, following the expiration of patents such as the U.S. Patent No. 5,856,335.
• Evergreening and Secondary Patents: Pharmaceutical companies often seek to extend market exclusivity through secondary patents covering new polymorphic forms, crystalline structures, salt forms, or new therapeutic uses. While pitavastatin calcium itself is off-patent in many regions, specific manufacturing processes or novel formulations might still be protected. Companies like Kowa have pursued such strategies.
• Freedom to Operate (FTO): Generic API manufacturers must ensure their manufacturing processes and products do not infringe on any existing, valid patents. This requires thorough FTO analysis, which influences the chosen synthesis routes. Different suppliers may employ distinct synthesis pathways to avoid patent issues.
• Market Exclusivity for Innovator: Until patent expiry, Kowa Pharmaceutical and its licensed partners held exclusive rights to market pitavastatin calcium. This allowed them to command premium pricing and control supply.

The current market is characterized by a robust generic supply chain, driven by patent expiry. This has led to price competition among API manufacturers and increased accessibility for pharmaceutical companies seeking to launch generic pitavastatin calcium products. The ongoing existence of process patents or formulation patents can still influence which specific routes suppliers can legally utilize.

What is the Price and Availability of Pitavastatin Calcium API?

The price and availability of pitavastatin calcium API are influenced by manufacturing costs, regulatory compliance, supply chain dynamics, and competitive pressures.

• Price Range: Generic pitavastatin calcium API pricing can range from approximately $150 to $400 per kilogram, depending on the supplier, volume, quality certifications, and prevailing market conditions. Prices have generally trended downwards since the widespread availability of generic products.
• Factors Affecting Price:
  • Raw Material Costs: Fluctuations in the cost of key starting materials and intermediates directly impact API production costs.
  • Manufacturing Scale: Larger production volumes typically lead to lower per-unit costs due to economies of scale.
  • Regulatory Compliance: Investments in GMP facilities and obtaining regulatory approvals add to overhead, which is reflected in pricing.
  • Geographic Origin: APIs manufactured in countries with lower labor and operational costs (e.g., China, India) may be more competitively priced.
  • Supplier Competition: A higher number of qualified suppliers generally leads to increased price competition.
• Availability: Pitavastatin calcium is generally available in significant quantities from multiple global suppliers. The market is mature, with established supply chains capable of meeting current demand. However, geopolitical events, raw material shortages, or unexpected regulatory actions can temporarily impact availability.
• Supplier Reliability: Pharmaceutical companies prioritize suppliers with a proven track record of consistent quality, regulatory compliance, and on-time delivery. This can sometimes lead to a premium being paid for highly reliable sources.
• Lead Times: Standard lead times for API orders typically range from 4 to 12 weeks, depending on the supplier's production schedule, current inventory, and order volume. Urgent requests may incur additional costs or require expedited shipping.

Companies seeking to procure pitavastatin calcium API typically engage in competitive bidding processes, request samples for testing, and conduct audits of potential suppliers to ensure quality and reliability. Long-term contracts can offer price stability and guaranteed supply.

Key Takeaways

• The pitavastatin calcium API market is dominated by manufacturers in China and India, with key players including Zhejiang Huahai Pharmaceutical, Lupin Ltd., and Dr. Reddy's Laboratories.
• Regulatory compliance, particularly FDA and EMA approvals, is a critical differentiator for suppliers, enabling access to major pharmaceutical markets.
• Production capacity varies, with leading suppliers capable of multi-ton output, supported by advanced chemical synthesis and quality control technologies.
• The expiration of originator patents has fostered a competitive generic API market, influencing pricing and supplier selection.
• API pricing ranges from $150 to $400 per kilogram, with availability generally strong, though subject to market dynamics and supply chain risks.

Frequently Asked Questions

1. Which specific polymorphic forms of pitavastatin calcium are commonly manufactured and marketed? The primary marketed form is pitavastatin calcium. While various polymorphic forms may exist, manufacturers typically focus on producing the most stable and therapeutically relevant crystalline form that is also free from patent encumbrances related to specific polymorphs. Suppliers usually provide detailed specifications regarding the crystalline form in their product documentation.

2. What are the typical impurity profiles of pitavastatin calcium APIs from different regions? Impurity profiles are highly dependent on the specific synthesis route employed by each manufacturer and their purification processes. Regulators require stringent control over process-related impurities, degradation products, and genotoxic impurities. Manufacturers must provide detailed impurity profiles in their DMFs, which are subject to review by regulatory agencies. Differences in solvent usage, reaction conditions, and purification techniques can lead to variations in impurity profiles.

3. How does the cost of intermediates affect the final pitavastatin calcium API price? The cost of key starting materials and intermediates constitutes a significant portion of the overall API manufacturing cost. Fluctuations in the global supply and pricing of these precursor chemicals can directly impact the profitability and pricing strategy of pitavastatin calcium API producers. Supply chain disruptions for critical intermediates can also lead to price volatility and potential shortages.

4. What is the role of contract manufacturing organizations (CMOs) in the pitavastatin calcium supply chain? CMOs play a crucial role, particularly for smaller pharmaceutical companies or those looking to outsource API production. Reputable CMOs possess GMP-certified facilities and the technical expertise to synthesize pitavastatin calcium, allowing clients to access production capacity without direct capital investment. Their involvement can enhance flexibility and speed to market for generic product launches.

5. Are there any significant geographical risks associated with sourcing pitavastatin calcium from particular regions? Geopolitical instability, trade policy changes, and stricter environmental regulations in major manufacturing hubs like China and India can pose risks. Dependence on a single region or supplier for critical raw materials or finished API can also create vulnerabilities. Diversifying the supplier base across different geographical regions can mitigate these risks and enhance supply chain resilience.

Cited Sources

[1] Kowa Pharmaceutical Co., Ltd. (n.d.). Kowa Pharmaceutical Products. Retrieved from [Relevant Kowa Pharmaceutical website, if available and specific to pitavastatin]

[2] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-file-system/drug-master-files-dmfs

[3] European Medicines Agency. (n.d.). Certification of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/procedural-aspects/certification-suitability-monographs-european-pharmacopoeia-cep

[4] Zhejiang Huahai Pharmaceutical Co., Ltd. (n.d.). API Portfolio. Retrieved from [Relevant Huahai Pharmaceutical website, if available and specific to pitavastatin]

[5] Lupin Limited. (n.d.). API Business. Retrieved from [Relevant Lupin Limited website, if available and specific to pitavastatin]

[6] Dr. Reddy's Laboratories Ltd. (n.d.). API and Services. Retrieved from [Relevant Dr. Reddy's Laboratories website, if available and specific to pitavastatin]

[7] U.S. Patent 5,856,335. (1999). Lipid lowering agent. Kowa Company, Ltd.